Evidence map›Paper›PMID 41927783›Full record

ArticleNPJ precision oncology2026

Multimodal AI model for early detection of hepatocellular carcinoma.

Si-Yu Jing, Xue-Liang Li, Hong Wen, Jing-Xuan Cai, Yong-Qi Bei, Xue-Lian Zhao, Zheng-Tao Zhang, Xiao-Han Fan, Yi-Ning Zou, Ling-Li Chen and 8 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Si-Yu Jing *Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, PR China.
Xue-Liang Li *Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, PR China.
Hong Wen *Department of Pathology, Zhongshan Hospital Fudan University, Shanghai, PR China.
Jing-Xuan CaiShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, PR China.
Yong-Qi BeiShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, PR China.
Xue-Lian ZhaoMolecular Pathology Center, Zhongshan Hospital, Fudan University, Shanghai, PR China.
Zheng-Tao ZhangState Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, PR China.
Xiao-Han FanDepartment of Pathology, Zhongshan Hospital Fudan University, Shanghai, PR China.
Yi-Ning ZouDepartment of Pathology, Zhongshan Hospital Fudan University, Shanghai, PR China.
Ling-Li ChenDepartment of Pathology, Zhongshan Hospital Fudan University, Shanghai, PR China.
Yu-Lin WangDepartment of Pathology, Zhongshan Hospital Fudan University, Shanghai, PR China.
Cai-Ying WangDepartment of Pathology, Zhongshan Hospital Fudan University, Shanghai, PR China.
Xin LiDepartment of Pathology, Zhongshan Hospital Fudan University, Shanghai, PR China.
Li-Li MengDepartment of Pathology, Zhongshan Hospital Fudan University, Shanghai, PR China.
Ping LinShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, PR China.
Xi YanShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, PR China.
Yuan JiDepartment of Pathology, Zhongshan Hospital Fudan University, Shanghai, PR China. ji.yuan@zs-hospital.sh.cn.
Hong LiShanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, PR China. lihong01@sinh.ac.cn.

Funding

National Natural Science Foundation of China 32300555National Natural Science Foundation of China T2122018Shanghai Municipal Science and Technology Commission 22JC1403002Shanghai Municipal Science and Technology Major Project, Shanghai Sailing Program 22YF1458000Shanghai Post-doctoral Excellence Program 2025190
6 · The paper itself

Abstract

Detection of early hepatocellular carcinoma (eHCC) is important for timely treatment and improved prognosis. However, it is challenging to distinguish eHCC from pre-malignant high-grade dysplastic nodules (HGDN). Here we developed an artificial intelligence (AI) derived computational framework to identify potential biomarkers and built classification models for eHCC and HGDN. A two-stage multiscale deep learning model (TMC-net) captured the subtle features based on H&E images, and outperformed the pathology foundation model and traditional histopathological features. The learned features were consistent with clinical diagnostic criteria and could be highlighted on the virtual images, assisting junior pathologists in improving the diagnostic accuracy. Four marker genes were screened through comparative transcriptome analysis. The multimodal model based on marker genes and histopathological features achieved AUROC of 0.8875 and 0.9500 on the internal and external test sets, respectively. We confirmed the morpho-phenotype correlations of these genes and found that the multimodal features were associated with patient prognosis in a broader HCC cohort. This study reveals histopathological and transcriptomic features of eHCC, and provides an optimized AI solution for assistant diagnosis.

Identifiers

PMID41927783
PMCPMC13216345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.